Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.35 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.35 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6094986 | 0.83 | ALDH1A1 (0.49) | CYP3A4CYP2C19CYP2C9CYP1A2ALDH1A1 | |
| SCHEMBL11112299 | 0.73 | ALDH1A1 (0.51) | CYP3A4CYP2C19CYP2C9CYP1A2ALDH1A1 | |
| SCHEMBL14046008 | 0.68 | MAPT (0.38) | CYP3A4CYP2C19CYP2C9CYP1A2PTGS1 | |
| SCHEMBL31137134 | 0.68 | LMNA (0.43) | KCNN4CYP2C19CYP2C9ALDH1A1GAA | |
| SCHEMBL28474714 | 0.68 | TSHR (0.46) | CYP2C19CYP2C9CYP1A2ALDH1A1SMN1; SMN2 | |
| SCHEMBL28478153 | 0.68 | TSHR (0.48) | CYP2C19CYP1A2ALDH1A1SMN1; SMN2GAA | |
| SCHEMBL11108113 | 0.68 | POLB (0.39) | CYP3A4KCNN4CYP2C19CYP2C9CYP1A2 | |
| SCHEMBL11105058 | 0.67 | CYP1A2 (0.42) | KCNN4CYP2C9CYP1A2ALDH1A1POLB | |
| SCHEMBL7818136 | 0.67 | ALDH1A1 (0.57) | CYP3A4CYP2C19CYP2C9ALDH1A1KDM4E | |
| SCHEMBL538597 | 0.67 | HSD17B10 (0.44) | CYP3A4CYP2C19CYP2C9CYP1A2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7138411-B2 | Substituted benzopyran derivatives for the treatment of inflammation | G.D. SEARLE & CO. (US) | 2006-11-21 | — | — | US | disclosed |
| US-7109211-B2 | Substituted benzopyran derivatives for the treatment of inflammation | PHARMACIA CORPORATION (OF PFIZER, INC.) (US) | 2006-09-19 | — | — | US | disclosed |
| US-20050049252-A1 | Substituted benzopyran derivatives for the treatment of inflammation | G.D. SEARLE & CO. (US) | 2005-03-03 | — | — | US | disclosed |
| US-20040127539-A1 | Antiangiogenic combination therapy for the treatment of cancer | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | disclosed |
| EP-1414526-A2 | ANTIANGIOGENIC COMBINATION THERAPY FOR THE TREATMENT OF CANCER | Pharmacia Corporation (US) | 2004-05-06 | — | — | EP | disclosed |
| US-20040038977-A1 | Substituted bezopyran derivatives for the treatment of inflammation | G.D. SEARLE & CO. | 2004-02-26 | — | — | US | disclosed |
| EP-0977748-B1 | SUBSTITUTED BENZOPYRAN DERIVATIVES FOR THE TREATMENT OF INFLAMMATION | SEARLE & CO (US) | 2003-03-26 | — | — | EP | disclosed |
| US-6492390-B2 | TREATING CYCLOOXYGENASE-2 MEDIATED DISORDERS. | G.D. SEARLE & CO. | 2002-12-10 | — | — | US | disclosed |
| WO-2002085459-A2 | ANTIANGIOGENIC COMBINATION THERAPY FOR THE TREATMENT OF CANCER | PHARMACIA CORPORATION (US) | 2002-10-31 | — | — | WO | disclosed |
| US-20020103141-A1 | Antiangiogenic combination therapy for the treatment of cancer | PHARMACIA CORPORATION | 2002-08-01 | — | — | US | disclosed |
| US-20020010206-A1 | Substituted benzopyran analogs for the treatment of inflammation | G.D. SEARLE & CO. (US) | 2002-01-24 | — | — | US | disclosed |
| US-6271253-B1 | CYCLOOXYGENASE INHIBITORS | G.D. SEARLE & CO. | 2001-08-07 | — | — | US | disclosed |
| US-6077850-A | USEFUL FOR TREATING CYCLOOXYGENASE-2 MEDIATED DISORDERS, SUCH AS INFLAMMATION AND INFLAMMATION-RELATED DISORDERS | G.D. SEARLE & CO. (US) | 2000-06-20 | — | — | US | disclosed |
| US-6034256-A | CYCLOOXYGEASE INHIBITOR | G.D. SEARLE & CO. (US) | 2000-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010206-A1 | Substituted benzopyran analogs for the treatment of inflammation | PTGS1, IL1R1, PTGES2 | CYP3A4 379/4885ELANE 218/4885KCNN4 4388/4885 |
| US-20040038977-A1 | Substituted bezopyran derivatives for the treatment of inflammation | PTGS1, PTGES2, IL1R1 | CYP3A4 476/4885ELANE 339/4885KCNN4 4558/4885 |
| US-20050049252-A1 | Substituted benzopyran derivatives for the treatment of inflammation | PTGES2, PTGS2, PTGER2 | CYP3A4 142/4885ELANE 110/4885KCNN4 4031/4885 |
| US-20020103141-A1 | Antiangiogenic combination therapy for the treatment of cancer | TOP2A, TOP2B, TOP1 | CYP3A4 2709/4885ELANE 977/4885KCNN4 4476/4885 |
| US-20040127539-A1 | Antiangiogenic combination therapy for the treatment of cancer | TOP2A, TOP2B, TOP1 | CYP3A4 2709/4885ELANE 977/4885KCNN4 4476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.